Lifeward prices 4M shares at 65c in public offering
Lifeward (LFWD) announced the pricing of a public offering of an aggregate of 4,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company's ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $2.6M before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the ordinary warrants, if fully exercised on a cash basis, will be approximately $2.6M. The Company intends to use the net proceeds from this offering for its continuing commercial efforts, working capital and general corporate purposes.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LFWD:
Disclaimer & DisclosureReport an Issue
Lifeward Announces Annual Meeting Date for 2025
Lifeward Announces New CEO Appointment Effective June 2025
Lifeward appoints Grant as new President, CEO
Lifeward Ltd. Reports Q1 2025 Financial Results
Lifeward Inc. Earnings Call: Optimism Amid Challenges
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Deadline Approaching: 3D Systems Corporation (DDD) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN 3D SYSTEMS CORPORATION (DDD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On March 26, 2025, 3D Systems released its fourth quarter and full year 2024 financial results, missing consensus estimates in non-GAAP earnings-per-share and sales revenue, citing 'lowers hardware systems sales due to macroeconomic factors that are negatively impacting demand.' The Company also reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program." The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing . . . which led to refinement of the milestone technical criteria." On this news, 3D Systems' stock price fell $0.57, or 21%, to close at $2.15 per share on March 27, 2025, thereby injuring investors. Then, on May 12, 2025, after market hours, 3D Systems released its first quarter 2025 financial results, missing consensus estimates due, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. The Company further disclosed that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68, or 26.6%, to close at $1.87 per share on May 13, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired 3D Systems securities during the Class Period, you may move the Court no later than August 12, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
an hour ago
- Yahoo
McCormick Q2 Earnings Beat Estimates, Organic Sales Grow
McCormick & Company, Incorporated MKC reported second-quarter fiscal 2025 results, with the top line increasing year over year but missing the Zacks Consensus Estimate. The bottom line was flat year over year but surpassed the consensus adjusted earnings of 69 cents per share were unchanged from the year-ago quarter. The Zacks Consensus Estimate was 65 cents per share. The comparable performance was driven by higher operating income and increased contributions from unconsolidated operations, partially offset by a less favorable tax rate resulting from discrete tax items. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) McCormick & Company, Incorporated price-consensus-eps-surprise-chart | McCormick & Company, Incorporated Quote This global leader in flavor generated net sales of $1,659.5 million, which was down from the Zacks Consensus Estimate of $1,663 million. However, the metric increased 1% from the year-ago period and included a 1% unfavorable currency impact. Organic sales grew 2% on favorable volume and product mix. McCormick's gross profit for the fiscal second quarter rose $3 million, reaching $622.8 million. The gross profit margin contracted 20 basis points (bps) to reach 37.5%, primarily due to increased costs associated with expanding capacity for growth and higher commodity prices. These pressures were partially offset by cost savings driven by the company's Comprehensive Continuous Improvement ('CCI') adjusted operating income increased 10%, totaling $259 million, with a 1% unfavorable impact from currency fluctuations. In constant currency, adjusted operating income increased 11%, largely due to lower selling, general and administrative (SG&A) expenses, driven by the timing shift of stock-based compensation expenses from the second quarter to the first quarter, along with ongoing cost savings from the CCI program, including SG&A streamlining initiatives. These gains were partially offset by lower gross margin, continued investment in brand marketing and higher technology spending. Consumer: Sales were $931 million, up 3% from the year-ago quarter's level, with minimal impact from currency fluctuations. Organic sales advanced 3%, driven by favorable volume and product mix. Regionally, sales grew 2.4% in the Americas, 4.9% in EMEA and 2.9% in APAC. Our model expected Consumer sales of $918 million for the Solutions: Sales in the segment decreased 1% to $729 million, with a 1% unfavorable currency impact. Organic sales were flat year over year, caused by a 1% increase from price, offset by a 1% decrease in volume and product mix. Flavor Solutions' sales in the Americas and EMEA inched down 1% and 4.7%, respectively. Its sales in APAC increased 3.1%. We anticipated Flavor Solutions' sales of $747 million for the quarter. McCormick exited the quarter with cash and cash equivalents of $124.1 million, long-term debt of $3,099.3 million and total shareholders' equity of $5,630.4 million. In the six months ended May 31, 2025, net cash provided by operating activities was $161.4 fiscal 2025, the company anticipates strong cash flow, driven by profitability and working capital initiatives. In addition, it expects to return a significant portion of this cash flow to shareholders through dividends. McCormick's fiscal 2025 outlook indicates its continued focus on strategic investments in key categories to strengthen volume trends and drive long-term profitable growth amid current uncertainty in the consumer and macroeconomic environment. The company's CCI program remains a key driver of growth investments and operating margin expansion. In addition, McCormick expects foreign currency fluctuations to negatively impact sales and adjusted operating income by 1% each, as well as adjusted earnings per share (EPS) by 2%.For fiscal 2025, management still expects net sales growth in the range of flat to increasing 2% (up 1-3% at constant currency). Sales are likely to be backed by volume-led growth across both company segments and a gradual improvement in China's expects adjusted operating income to grow 3-5% and increase 4-6% at constant currency. Management envisions fiscal 2025 adjusted EPS in the band of $3.03-$3.08, which indicates a 3-5% increase from the year-ago period. On a constant currency basis, the adjusted EPS is expected to increase 5-7%. On a GAAP basis, McCormick projects fiscal 2025 earnings in the range of $2.98-$3.03 per share, indicating 2-4% year-over-year Zacks Rank #4 (Sell) stock has lost 9.3% in the past three months compared with the industry's decline of 5.3%. Image Source: Zacks Investment Research BRF S.A. BRFS raises, produces and slaughters poultry and pork for the processing, production and sale of fresh meat, processed products, pasta, margarine, pet food and other products. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks Zacks Consensus Estimate for BRF S.A.'s current fiscal-year earnings implies growth of 27.8% from the prior-year levels. BRFS delivered a trailing four-quarter earnings surprise of 5.4%, on International MDLZ manufactures, markets and sells snack food and beverage products. It presently has a Zacks Rank of 2. MDLZ delivered a trailing four-quarter earnings surprise of 9.8%, on consensus estimate for Mondelez's current fiscal-year sales implies growth of 5.3% from the year-ago Group AB OTLY, an oatmilk company, provides a range of plant-based dairy products made from oats. It presently has a Zacks Rank of 2. OTLY delivered a trailing four-quarter earnings surprise of 25.1%, on consensus estimate for Oatly Group's current fiscal-year sales and earnings implies growth of 2.3% and 63.8%, respectively, from the year-ago figures. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McCormick & Company, Incorporated (MKC) : Free Stock Analysis Report BRF S.A. (BRFS) : Free Stock Analysis Report Mondelez International, Inc. (MDLZ) : Free Stock Analysis Report Oatly Group AB Sponsored ADR (OTLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
an hour ago
- Business Wire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ('Hims & Hers' or 'the Company') (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 25, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Hims & Hers was engaged in marketing activities that Novo Nordisk would describe as 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The Company was at risk of Novo Nordisk terminating their partnership. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Hims & Hers, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
